Don O’Hearn is K2M, Inc.’s new Senior Vice President of Sales in the Americas.
O’Hearn to Lead K2M’s Sales in the Americas
1 min read Premium comments
The company announcement on December 13 stated that the appointment of O’Hearn is “an important milestone in the company’s strategic plan to become a global leader in the spine market.”
With O’Hearn’s 20 years of medical industry expertise, K2M’s President and CEO Eric Major said, “Don brings incredible experience to our team and demonstrates our investment in rapidly expanding the global business. He will provide leadership in the development of an exclusive sales organization, building a presence throughout the Americas. I’m excited to work with Don, who will undoubtedly play a significant role in helping K2M offer the best solutions for physicians and patients around the world.”
Seventeen of O’Hearn’s 20 years in industry, were spent in the medical device field across the U.S., Canada and Latin America. According to O’Hearn’s LinkedIn site, his experience includes serving as senior VP sales, America at AGA, part of St. Jude Medical, Inc. since November 2010 and VP U.S. sales operations at Medtronic, Inc. for three and a half years from 2006 to 2009.
“It’s an incredible time to be joining K2M, ” said O’Hearn in a prepared statement. “Its rapidly growing product portfolio coupled with its continued global expansion is compelling, particularly at a time when many in the industry are really regrouping for the future.”
O’Hearn holds a Masters of Business Administration from the University of Chicago Graduate School of Business with a concentration in Finance and Marketing, a Master of Science in Biochemistry and Biophysics from Yale University, and a Bachelor of Science in Molecular Biology from the University of Wisconsin.
According to O’Hearn’s Facebook page, he’s married and probably a Green Bay Packer fan, having graduated from Green Bay East High School.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.